Inclusion criteria: Advanced Solid Tumor. Patients with RET-altered tumors who have progressed following first-generation selective RET inhibitor (SRI) therapy and patients with RET-altered tumors with no prior SRI therapy.
Sponsor/Collaborator: Ellipses Pharma
Contact and Locations:
Study Contact: Sonia Serrano
Phone Number: +44 (0)20 3743 0992
Email: sonia@ellipses.life
Locations: https://clinicaltrials.gov/study/NCT05443126#contacts-and-locations
Mechanism of action: EP0031 selectively binds to various RET fusions and mutations, including solvent front resistance mutations.
Phases: Phase 1, Phase 2
NCT Number: NCT05443126
Status: Recruiting
